top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Bernard Kelley Biography and Net Worth

Director of Codexis

Bernard J. Kelley serves as an Independent Chairman of the Board of the Board of the Company. Mr. Kelley brings to our board of directors experience in pharmaceutical manufacturing, as well as senior management and financial operations experience. From 1993 to 2002, Mr. Kelley was the President of the Merck Manufacturing Division, a division of Merck & Co., Inc. (“Merck”), a global pharmaceutical company, and he served as a member of the Merck Management Committee from 1995 to 2002. Mr. Kelley previously served on the board of directors of Aegis Analytical Corporation, an enterprise software company, from 2004 to 2006, and on the board of directors and compensation and audit committees of MAP Pharmaceuticals, Inc., a biotechnology company focused on developing inhalation-based therapies which was acquired by Allergan, Inc. in March 2013, from May 2007 to March 2013. In addition, Mr. Kelley serves as a member of the board of trustees and the finance committee of the Catholic Foundation of Greater Philadelphia, a non-profit organization based in Philadelphia, and as a member of the board of trustees and finance committee of the National Liberty Museum, also a non-profit organization based in Philadelphia. Mr. Kelley holds a B.S. in engineering from the U.S. Naval Academy.

What is Bernard J. Kelley's net worth?: The estimated net worth of Bernard J. Kelley is at least $581,303.52 as of April 21st, 2021. Mr. Kelley owns 206,136 shares of Codexis stock worth more than $581,304 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Kelley may own. Learn More about Bernard J. Kelley's net worth.
How do I contact Bernard J. Kelley?: The corporate mailing address for Mr. Kelley and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Bernard J. Kelley's contact information.
Has Bernard J. Kelley been buying or selling shares of Codexis?: Bernard J. Kelley has not been actively trading shares of Codexis within the last three months. Most recently, Bernard J. Kelley sold 2,500 shares of the business's stock in a transaction on Wednesday, April 21st. The shares were sold at an average price of $22.64, for a transaction totalling $56,600.00. Following the completion of the sale, the director now directly owns 206,136 shares of the company's stock, valued at $4,666,919.04. Learn More on Bernard J. Kelley's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, Codexis insiders bought shares 3 times. They purchased a total of 32,484 shares worth more than $55,402.80. In the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 20,000 shares worth more than $42,200.00. The most recent insider tranaction occured on November, 15th when Director Byron L Dorgan sold 20,000 shares worth more than $42,200.00. Insiders at Codexis own 6.3% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 11/15/2023.

Bernard J. Kelley Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/21/2021	Sell	2,500	$22.64	$56,600.00	206,136
1/21/2021	Sell	2,500	$24.98	$62,450.00	208,636
10/21/2020	Sell	2,500	$14.00	$35,000.00	211,136
7/21/2020	Sell	2,500	$12.79	$31,975.00	213,636
4/21/2020	Sell	2,500	$10.58	$26,450.00	207,184
1/21/2020	Sell	2,500	$18.00	$45,000.00	209,684
9/6/2019	Sell	14,684	$13.87	$203,667.08	226,868
9/21/2018	Sell	10,207	$18.12	$184,950.84	215,461
8/30/2018	Sell	16,666	$17.15	$285,821.90	242,334
6/21/2018	Sell	10,206	$16.58	$169,215.48	225,668
3/21/2018	Sell	10,206	$12.22	$124,717.32
8/24/2016	Sell	12,643	$4.26	$53,859.18	234,906
9/10/2015	Sell	5,200	$3.45	$17,940.00	193,146

Bernard J. Kelley Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $2.80

$2.75

$2.91

50 Day Range

MA: $3.32

$2.69

$4.65

2 Week Range

Now: $2.80

$1.45

$4.91

Volume

213,453 shs

Average Volume

558,127 shs

Market Capitalization

$196.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01